Blake Insomnia Therapeutics Inc. and Sajo Consulting LLC announced completion of a joint venture agreement for the development and commercialization of a series of oral drug products to aid in the treatment of insomnia. The joint venture intends to develop products to treat transient insomnia using Blake's proprietary Zleepax formula. Clinical trials are planned for second quarter of 2017 pending approval of a New Drug Application in Canada with US and International submissions to follow later.